JP6641263B2 - 神経障害性疼痛の処置方法 - Google Patents

神経障害性疼痛の処置方法 Download PDF

Info

Publication number
JP6641263B2
JP6641263B2 JP2016509176A JP2016509176A JP6641263B2 JP 6641263 B2 JP6641263 B2 JP 6641263B2 JP 2016509176 A JP2016509176 A JP 2016509176A JP 2016509176 A JP2016509176 A JP 2016509176A JP 6641263 B2 JP6641263 B2 JP 6641263B2
Authority
JP
Japan
Prior art keywords
alkyl
hydroxy
group
pain
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016509176A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016528165A (ja
JP2016528165A5 (cg-RX-API-DMAC7.html
Inventor
上野　隆司
隆司 上野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Publication of JP2016528165A publication Critical patent/JP2016528165A/ja
Publication of JP2016528165A5 publication Critical patent/JP2016528165A5/ja
Application granted granted Critical
Publication of JP6641263B2 publication Critical patent/JP6641263B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/26—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • C07C53/134—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016509176A 2013-08-22 2014-08-21 神経障害性疼痛の処置方法 Expired - Fee Related JP6641263B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361868750P 2013-08-22 2013-08-22
US61/868,750 2013-08-22
US201361918124P 2013-12-19 2013-12-19
US61/918,124 2013-12-19
PCT/JP2014/072508 WO2015025980A1 (en) 2013-08-22 2014-08-21 Method for treating neuropathic pain

Publications (3)

Publication Number Publication Date
JP2016528165A JP2016528165A (ja) 2016-09-15
JP2016528165A5 JP2016528165A5 (cg-RX-API-DMAC7.html) 2017-09-28
JP6641263B2 true JP6641263B2 (ja) 2020-02-05

Family

ID=52480928

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016509176A Expired - Fee Related JP6641263B2 (ja) 2013-08-22 2014-08-21 神経障害性疼痛の処置方法

Country Status (4)

Country Link
US (1) US20150057351A1 (cg-RX-API-DMAC7.html)
EP (1) EP3035925A4 (cg-RX-API-DMAC7.html)
JP (1) JP6641263B2 (cg-RX-API-DMAC7.html)
WO (1) WO2015025980A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108366984A (zh) 2015-09-22 2018-08-03 灰色视觉公司 用于治疗眼部病症的化合物和组合物
BR112019011961A2 (pt) * 2017-01-06 2019-11-05 Clexio Bioscienses Ltd formulação tópica, método para prover tratamento não-sistêmico prolongado para dor em um indivíduo humano necessitando do mesmo, método para formar um depósito subcutâneo de detomidina ou um sal do mesmo em um indivíduo humano, formulação tópica e método para prover o tratamento para dor em um indivíduo humano necessitando do mesmo

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
TW249226B (cg-RX-API-DMAC7.html) 1990-04-04 1995-06-11 Aderk Ueno Kk
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
WO1997047595A1 (en) 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Endothelin antagonist
NZ523851A (en) * 2000-07-21 2004-09-24 Ortho Mcneil Pharm Inc A method for use of carbamate enantiomers in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
JPWO2002066030A1 (ja) * 2001-02-22 2004-06-17 小野薬品工業株式会社 ジクロフェナクとオルノプロスチルからなる医薬組成物
BR0212233A (pt) * 2001-08-31 2004-10-05 Sucampo Ag Abridor de canal de cloreto
KR100837019B1 (ko) * 2004-05-11 2008-06-10 인사이트 코포레이션 케모카인 수용체 조절제로서3-(4-헤테로아릴사이클로헥실아미노)사이클로펜탄카복스아마이드
DE602006018583D1 (de) * 2005-03-04 2011-01-13 Sucampo Ag Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
JP2010106019A (ja) * 2008-10-02 2010-05-13 Kanazawa Univ リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤
US20110034424A1 (en) * 2009-06-30 2011-02-10 Sucampo Ag Method for the long term nsaid use
MX359697B (es) * 2011-08-05 2018-10-08 Sucampo Ag Metodo para tratar esquizofrenia.

Also Published As

Publication number Publication date
JP2016528165A (ja) 2016-09-15
EP3035925A1 (en) 2016-06-29
WO2015025980A1 (en) 2015-02-26
EP3035925A4 (en) 2017-03-29
US20150057351A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
KR100886598B1 (ko) 15-케토-프로스타글란딘을 가지는, 약물-유발 변비 치료용조성물
US20110275711A1 (en) Method for treating macular edema
JP2011512323A (ja) 幹細胞の成長を調節するための方法および組成物
JP2010532314A (ja) Ｎｓａｉｄおよびプロスタグランジン化合物の医薬的組み合わせ
JP6641263B2 (ja) 神経障害性疼痛の処置方法
JP2017048255A (ja) オピオイドおよびプロスタグランジン化合物の医薬的組み合わせ
JP2017222708A (ja) 統合失調症の処置方法
KR100681221B1 (ko) 문맥압 상승 억제제
US20100305203A1 (en) Method for modulating claudin mediated functions
JP2010519177A (ja) ミトコンドリアを保護するための組成物および方法
US8569279B2 (en) Method for modulating claudin mediated functions
JP2016056191A (ja) 腫瘍を処置するための医薬的組合せ
JP2015514681A (ja) 下痢を伴う過敏性腸症候群の処置方法
US20160120840A1 (en) Method and composition for treating nonerosive reflux disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190524

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190823

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191227

R150 Certificate of patent or registration of utility model

Ref document number: 6641263

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees